Author

Sean Keegan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

Caroline P. Bullock· 2 shared Sol ShenkeriD· 2 shared Adam S. Lazorchak· 1 shared Alex SmashnoviD· 1 shared Amy Lundberg· 1 shared Anja F. Hohmann· 1 shared Anne E. DodsoniD· 1 shared Ashish YeriiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Caroline P. Bullock

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Dual-inactivation of Regnase-1 and SOCS1 rewires exhausted CD8+ T cell fate to enhance anti-tumor functionality

Isabelle Le Mercier, David Monteiro, Katarina Halpin-Veszeleiova, Karrie Ka Wai Wong, Anne E. Dodson, Gustavo J. Martinez, Dominick A. Matos, Bashar M. Hamza, Ashish Yeri, Seamus McKenney, Sharon Lin, Nicole Protheroe, Alex Smashnov, Paul Dunbar, Mitali Ghose, , Micah J. Benson

This study identifies Regnase-1 and SOCS1 dual-inactivation as a strategy to enhance anti-tumor functionality of CD8+ T cells by rewiring their differentiation and effector state.

bioRxiv · Jan 23, 2026 · PreprintImmunology

A Precision Gene Engineered B Cell Medicine Producing Sustained Levels of Active Factor IX for Hemophilia B Therapy

Hanlan Liu, Swati Singh, Timothy Mullen, Caroline P. Bullock, Sean Keegan, Troy Patterson, Sakshisingh Thakur, Amy Lundberg, Sol Shenker, Ryan Couto, Charuta Yadav, Shamael R. Dastagir, Lily Yuanzhi Li, Wayne Bainter, Ella Liberzon, , Richard A. Morgan

This paper describes a gene-engineered B Cell Medicine (BE-101) that produces sustained active factor IX for hemophilia B therapy, showing durable and redosable effects in mice.

Molecular Therapy · Sep 5, 2025Peer-reviewedPharmacology & Toxicology